LEVODOPA

Levodopa Adverse Events Reported to the FDA Over Time

How are Levodopa adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Levodopa, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Levodopa is flagged as the suspect drug causing the adverse event.

Most Common Levodopa Adverse Events Reported to the FDA

What are the most common Levodopa adverse events reported to the FDA?

Dyskinesia	152 (2.38%)
Drug Ineffective	106 (1.66%)
Tremor	105 (1.65%)
Fall	89 (1.4%)
Condition Aggravated	85 (1.33%)
Gait Disturbance	78 (1.22%)
Hallucination	74 (1.16%)
Hallucination, Visual	67 (1.05%)
Dopamine Dysregulation Syndrome	65 (1.02%)
Hypersexuality	64 (1%)
Nausea	63 (.99%)
	Show More
Anxiety	62 (.97%)
Confusional State	60 (.94%)
Pathological Gambling	59 (.93%)
Drug Effect Decreased	57 (.89%)
On And Off Phenomenon	57 (.89%)
Agitation	55 (.86%)
Drug Interaction	55 (.86%)
Vomiting	53 (.83%)
Neuroleptic Malignant Syndrome	51 (.8%)
Muscle Rigidity	50 (.78%)
Somnolence	48 (.75%)
Delirium	47 (.74%)
Insomnia	44 (.69%)
Depression	42 (.66%)
Asthenia	40 (.63%)
Delusion	40 (.63%)
Fatigue	40 (.63%)
Aggression	39 (.61%)
Dizziness	39 (.61%)
Abnormal Behaviour	37 (.58%)
Weight Decreased	37 (.58%)
Dyspnoea	36 (.56%)
Muscle Spasms	36 (.56%)
Pneumonia	34 (.53%)
Dehydration	32 (.5%)
Dysphagia	32 (.5%)
Overdose	31 (.49%)
Psychotic Disorder	31 (.49%)
Hyperhidrosis	30 (.47%)
Drug Abuse	29 (.45%)
Pain	29 (.45%)
Movement Disorder	28 (.44%)
Orthostatic Hypotension	28 (.44%)
Constipation	27 (.42%)
Loss Of Consciousness	27 (.42%)
Hypotension	26 (.41%)
Rhabdomyolysis	26 (.41%)
Bradykinesia	25 (.39%)
Dystonia	25 (.39%)
Musculoskeletal Stiffness	25 (.39%)
Renal Failure Acute	24 (.38%)
Impulse-control Disorder	23 (.36%)
Jealous Delusion	23 (.36%)
Oedema Peripheral	23 (.36%)
Pneumonia Aspiration	23 (.36%)
Balance Disorder	22 (.34%)
General Physical Health Deteriorati...	22 (.34%)
Obsessive-compulsive Disorder	22 (.34%)
Compulsive Shopping	21 (.33%)
Diarrhoea	21 (.33%)
Aphasia	20 (.31%)
Feeling Abnormal	20 (.31%)
Pain In Extremity	20 (.31%)
Pyrexia	20 (.31%)
Abasia	19 (.3%)
Aspartate Aminotransferase Increase...	19 (.3%)
Blood Creatine Phosphokinase Increa...	19 (.3%)
Disorientation	19 (.3%)
Hypomania	19 (.3%)
Irritability	19 (.3%)
Motor Dysfunction	19 (.3%)
Persecutory Delusion	19 (.3%)
Cerebral Atrophy	18 (.28%)
Dysarthria	18 (.28%)
Paranoia	18 (.28%)
Sudden Onset Of Sleep	18 (.28%)
Completed Suicide	17 (.27%)
Dysphonia	17 (.27%)
Road Traffic Accident	17 (.27%)
Syncope	17 (.27%)
Hypertension	16 (.25%)
Stereotypy	16 (.25%)
Akinesia	15 (.24%)
Alanine Aminotransferase Increased	15 (.24%)
Headache	15 (.24%)
Parkinsonism	15 (.24%)
Product Substitution Issue	15 (.24%)
Cerebrovascular Accident	14 (.22%)
Chest Pain	14 (.22%)
Convulsion	14 (.22%)
Drug Withdrawal Syndrome	14 (.22%)
Erythema	14 (.22%)
Hypoaesthesia	14 (.22%)
Ileus	14 (.22%)
Malaise	14 (.22%)
Marital Problem	14 (.22%)
Paralysis	14 (.22%)
Posture Abnormal	14 (.22%)
Activities Of Daily Living Impaired	13 (.2%)
Coronary Artery Dissection	13 (.2%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Levodopa, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Levodopa is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Levodopa

What are the most common Levodopa adverse events reported to the FDA?

Movement Disorders	532 (8.34%)
Neurological	404 (6.33%)
Therapeutic And Nontherapeutic Effe...	310 (4.86%)
Disturbances In Thinking	268 (4.2%)
Gastrointestinal Signs	206 (3.23%)
Anxiety Disorders	171 (2.68%)
Muscle	158 (2.48%)
Injuries	145 (2.27%)
Respiratory	139 (2.18%)
Psychiatric	138 (2.16%)
Impulse Control	136 (2.13%)
	Show More
Deliria	126 (1.98%)
Medication Errors	116 (1.82%)
Musculoskeletal And Connective Tiss...	94 (1.47%)
Sleep Disorders	89 (1.4%)
Infections - Pathogen Unspecified	86 (1.35%)
Sexual Dysfunctions, Disturbances A...	86 (1.35%)
Epidermal And Dermal Conditions	84 (1.32%)
Cardiac Arrhythmias	81 (1.27%)
Neuromuscular	78 (1.22%)
Personality Disorders	78 (1.22%)
Hematology Investigations	73 (1.14%)
Gastrointestinal Motility And Defec...	70 (1.1%)
Lifestyle Issues	66 (1.03%)
Depressed Mood Disorders	65 (1.02%)
Decreased And Nonspecific Blood Pre...	64 (1%)
Renal Disorders	60 (.94%)
Mental Impairment	58 (.91%)
Hepatobiliary	57 (.89%)
Electrolyte And Fluid Balance Condi...	53 (.83%)
Physical Examination Topics	53 (.83%)
Lower Respiratory Tract Disorders	51 (.8%)
Psychiatric And Behavioural Symptom...	51 (.8%)
Cardiac And Vascular Investigations	47 (.74%)
Hepatic And Hepatobiliary	46 (.72%)
Mood Disorders	44 (.69%)
Schizophrenia And Other Psychotic	44 (.69%)
Changes In Physical Activity	41 (.64%)
Urinary Tract Signs	40 (.63%)
Suicidal And Self-injurious Behavio...	39 (.61%)
Enzyme	36 (.56%)
Central Nervous System Vascular	35 (.55%)
Skin Appendage Conditions	32 (.5%)
Manic And Bipolar Mood Disorders	30 (.47%)
Vision	29 (.45%)
Appetite And General Nutritional	28 (.44%)
Coronary Artery	28 (.44%)
Body Temperature Conditions	27 (.42%)
Encephalopathies	27 (.42%)
Bone And Joint Injuries	26 (.41%)
Product Quality Issues	26 (.41%)
Renal And Urinary Tract Investigati...	25 (.39%)
Structural Brain	25 (.39%)
Joint	24 (.38%)
Seizures	23 (.36%)
Water, Electrolyte And Mineral	23 (.36%)
Ocular Neuromuscular	22 (.34%)
Sleep Disturbances	22 (.34%)
Fatal Outcomes	21 (.33%)
Allergic Conditions	20 (.31%)
Gastrointestinal Stenosis And Obstr...	20 (.31%)
Headaches	19 (.3%)
Oral Soft Tissue Conditions	19 (.3%)
Pleural	19 (.3%)
Neurological, Special Senses And Ps...	18 (.28%)
Cardiac Disorder Signs	17 (.27%)
Family Issues	16 (.25%)
Glucose Metabolism Disorders	16 (.25%)
Hemolyses And Related Conditions	16 (.25%)
Procedural And Device Related Injur...	16 (.25%)
Tongue Conditions	16 (.25%)
Vascular Hypertensive	16 (.25%)
Chemical Injury And Poisoning	15 (.24%)
Vascular	15 (.24%)
Communication Disorders	14 (.22%)
Eye	14 (.22%)
Metabolic, Nutritional And Blood Ga...	14 (.22%)
Viral Infectious	14 (.22%)
Legal Issues	13 (.2%)
Platelet	13 (.2%)
Therapeutic Procedures And Supporti...	13 (.2%)
Peripheral Neuropathies	12 (.19%)
White Blood Cell	12 (.19%)
Anemias Nonhemolytic And Marrow Dep...	11 (.17%)
Bronchial Disorders	11 (.17%)
Exocrine Pancreas Conditions	11 (.17%)
Investigations, Imaging And Histopa...	11 (.17%)
Myocardial	11 (.17%)
Bacterial Infectious	10 (.16%)
Dental And Gingival Conditions	10 (.16%)
Musculoskeletal And Connective Tiss...	10 (.16%)
Toxicology And Therapeutic Drug Mon...	10 (.16%)
Economic And Housing Issues	9 (.14%)
Gastrointestinal Conditions	9 (.14%)
Gastrointestinal Inflammatory Condi...	9 (.14%)
Heart Failures	9 (.14%)
Peritoneal And Retroperitoneal Cond...	9 (.14%)
Protein And Chemistry Analyses	9 (.14%)
Acid-base	8 (.13%)
Cranial Nerve Disorders	7 (.11%)
Hematological And Lymphoid Tissue T...	7 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Levodopa, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Levodopa is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.